Corticotropin-releasing hormone inhibition of paradoxical growth hormone response to thyrotropin-releasing hormone in insulin-dependent diabetics

A. Barbarino, S. M. Corsello, A. Tofani, R. Sciuto, S. Della Casa, C. A. Rota, S. Colasanti, A. Barini

Research output: Contribution to journalArticle

Abstract

A paradoxical growth hormone (GH) response to thyrotropin-releasing hormone (TRH) has been observed in type 1 diabetic patients and was hypothetically attributed to a reduced hypothalamic somatostatin tone. We have previously reported that corticotropin-releasing hormone (CRH) inhibits GH response to growth hormone-releasing hormone (GHRH) in normal subjects, possibly by an increased release of somatostatin. To study the effect of CRH on anomalous GH response to TRH, we tested with TRH (200 μg intravenously [IV]) and CRH (100 μg IV) + TRH (200 μg IV) 13 patients (six males and seven women) affected by insulin-dependent diabetes mellitus. A paradoxical GH response to TRH was observed in seven of 13 patients, one man and six women. In these subjects, the simultaneous administration of CRH and TRH significantly reduced the GH response to TRH, as assessed by both the maximal GH mean peak ± SE (2.18 ± 0.67 v 9.2 ± 1.26 μg/L, P <0.005) and the area under the curve (AUC) ± SE (187 ± 32 v 567 ± 35 μg · min/L, P <.001). CRH had no effect on TRH-induced thyroid-stimulating hormone (TSH) release. Our data demonstrate that the paradoxical GH response to TRH in patients with type 1 diabetes mellitus is blocked by CRH administration. This CRH action may be due to an enhanced somatostatin release. Our data also show that exogenous CRH has no effect on TSH response to TRH, thus suggesting the existence of separate pathways in the neuroregulation of GH and TSH secretion.

Original languageEnglish
Pages (from-to)949-953
Number of pages5
JournalMetabolism
Volume41
Issue number9
DOIs
Publication statusPublished - 1992

Fingerprint

Thyrotropin-Releasing Hormone
Corticotropin-Releasing Hormone
Growth Hormone
Insulin
Thyrotropin
Somatostatin
Type 1 Diabetes Mellitus
Growth Hormone-Releasing Hormone
Area Under Curve

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Corticotropin-releasing hormone inhibition of paradoxical growth hormone response to thyrotropin-releasing hormone in insulin-dependent diabetics. / Barbarino, A.; Corsello, S. M.; Tofani, A.; Sciuto, R.; Casa, S. Della; Rota, C. A.; Colasanti, S.; Barini, A.

In: Metabolism, Vol. 41, No. 9, 1992, p. 949-953.

Research output: Contribution to journalArticle

Barbarino, A. ; Corsello, S. M. ; Tofani, A. ; Sciuto, R. ; Casa, S. Della ; Rota, C. A. ; Colasanti, S. ; Barini, A. / Corticotropin-releasing hormone inhibition of paradoxical growth hormone response to thyrotropin-releasing hormone in insulin-dependent diabetics. In: Metabolism. 1992 ; Vol. 41, No. 9. pp. 949-953.
@article{fefd7954649a44fb83538962ebd8b434,
title = "Corticotropin-releasing hormone inhibition of paradoxical growth hormone response to thyrotropin-releasing hormone in insulin-dependent diabetics",
abstract = "A paradoxical growth hormone (GH) response to thyrotropin-releasing hormone (TRH) has been observed in type 1 diabetic patients and was hypothetically attributed to a reduced hypothalamic somatostatin tone. We have previously reported that corticotropin-releasing hormone (CRH) inhibits GH response to growth hormone-releasing hormone (GHRH) in normal subjects, possibly by an increased release of somatostatin. To study the effect of CRH on anomalous GH response to TRH, we tested with TRH (200 μg intravenously [IV]) and CRH (100 μg IV) + TRH (200 μg IV) 13 patients (six males and seven women) affected by insulin-dependent diabetes mellitus. A paradoxical GH response to TRH was observed in seven of 13 patients, one man and six women. In these subjects, the simultaneous administration of CRH and TRH significantly reduced the GH response to TRH, as assessed by both the maximal GH mean peak ± SE (2.18 ± 0.67 v 9.2 ± 1.26 μg/L, P <0.005) and the area under the curve (AUC) ± SE (187 ± 32 v 567 ± 35 μg · min/L, P <.001). CRH had no effect on TRH-induced thyroid-stimulating hormone (TSH) release. Our data demonstrate that the paradoxical GH response to TRH in patients with type 1 diabetes mellitus is blocked by CRH administration. This CRH action may be due to an enhanced somatostatin release. Our data also show that exogenous CRH has no effect on TSH response to TRH, thus suggesting the existence of separate pathways in the neuroregulation of GH and TSH secretion.",
author = "A. Barbarino and Corsello, {S. M.} and A. Tofani and R. Sciuto and Casa, {S. Della} and Rota, {C. A.} and S. Colasanti and A. Barini",
year = "1992",
doi = "10.1016/0026-0495(92)90119-U",
language = "English",
volume = "41",
pages = "949--953",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Corticotropin-releasing hormone inhibition of paradoxical growth hormone response to thyrotropin-releasing hormone in insulin-dependent diabetics

AU - Barbarino, A.

AU - Corsello, S. M.

AU - Tofani, A.

AU - Sciuto, R.

AU - Casa, S. Della

AU - Rota, C. A.

AU - Colasanti, S.

AU - Barini, A.

PY - 1992

Y1 - 1992

N2 - A paradoxical growth hormone (GH) response to thyrotropin-releasing hormone (TRH) has been observed in type 1 diabetic patients and was hypothetically attributed to a reduced hypothalamic somatostatin tone. We have previously reported that corticotropin-releasing hormone (CRH) inhibits GH response to growth hormone-releasing hormone (GHRH) in normal subjects, possibly by an increased release of somatostatin. To study the effect of CRH on anomalous GH response to TRH, we tested with TRH (200 μg intravenously [IV]) and CRH (100 μg IV) + TRH (200 μg IV) 13 patients (six males and seven women) affected by insulin-dependent diabetes mellitus. A paradoxical GH response to TRH was observed in seven of 13 patients, one man and six women. In these subjects, the simultaneous administration of CRH and TRH significantly reduced the GH response to TRH, as assessed by both the maximal GH mean peak ± SE (2.18 ± 0.67 v 9.2 ± 1.26 μg/L, P <0.005) and the area under the curve (AUC) ± SE (187 ± 32 v 567 ± 35 μg · min/L, P <.001). CRH had no effect on TRH-induced thyroid-stimulating hormone (TSH) release. Our data demonstrate that the paradoxical GH response to TRH in patients with type 1 diabetes mellitus is blocked by CRH administration. This CRH action may be due to an enhanced somatostatin release. Our data also show that exogenous CRH has no effect on TSH response to TRH, thus suggesting the existence of separate pathways in the neuroregulation of GH and TSH secretion.

AB - A paradoxical growth hormone (GH) response to thyrotropin-releasing hormone (TRH) has been observed in type 1 diabetic patients and was hypothetically attributed to a reduced hypothalamic somatostatin tone. We have previously reported that corticotropin-releasing hormone (CRH) inhibits GH response to growth hormone-releasing hormone (GHRH) in normal subjects, possibly by an increased release of somatostatin. To study the effect of CRH on anomalous GH response to TRH, we tested with TRH (200 μg intravenously [IV]) and CRH (100 μg IV) + TRH (200 μg IV) 13 patients (six males and seven women) affected by insulin-dependent diabetes mellitus. A paradoxical GH response to TRH was observed in seven of 13 patients, one man and six women. In these subjects, the simultaneous administration of CRH and TRH significantly reduced the GH response to TRH, as assessed by both the maximal GH mean peak ± SE (2.18 ± 0.67 v 9.2 ± 1.26 μg/L, P <0.005) and the area under the curve (AUC) ± SE (187 ± 32 v 567 ± 35 μg · min/L, P <.001). CRH had no effect on TRH-induced thyroid-stimulating hormone (TSH) release. Our data demonstrate that the paradoxical GH response to TRH in patients with type 1 diabetes mellitus is blocked by CRH administration. This CRH action may be due to an enhanced somatostatin release. Our data also show that exogenous CRH has no effect on TSH response to TRH, thus suggesting the existence of separate pathways in the neuroregulation of GH and TSH secretion.

UR - http://www.scopus.com/inward/record.url?scp=0026657555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026657555&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(92)90119-U

DO - 10.1016/0026-0495(92)90119-U

M3 - Article

C2 - 1355581

AN - SCOPUS:0026657555

VL - 41

SP - 949

EP - 953

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 9

ER -